Literature DB >> 15000267

Practice guideline for the treatment of patients with schizophrenia, second edition.

Anthony F Lehman, Jeffrey A Lieberman, Lisa B Dixon, Thomas H McGlashan, Alexander L Miller, Diana O Perkins, Julie Kreyenbuhl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15000267

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  462 in total

1.  A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections.

Authors:  Amlan K Das; Abid Malik; Peter M Haddad
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

Review 2.  Is rational antipsychotic polytherapy feasible? A selective review.

Authors:  Rune Andreas Kroken; Erik Johnsen
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

3.  Clozapine: a distinct, poorly understood and under-used molecule.

Authors:  Ridha Joober; Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

4.  High rates of psychosis for black inpatients in Padua and Montreal: different contexts, similar findings.

Authors:  G Eric Jarvis; Irene Toniolo; Andrew G Ryder; Francesco Sessa; Carla Cremonese
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-02-18       Impact factor: 4.328

Review 5.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Authors:  Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

6.  Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries.

Authors:  Sengwee Toh; Qian Li; T Craig Cheetham; William O Cooper; Robert L Davis; Sascha Dublin; Tarek A Hammad; De-Kun Li; Pamala A Pawloski; Simone P Pinheiro; Marsha A Raebel; Pamela E Scott; David H Smith; William V Bobo; Jean M Lawrence; Inna Dashevsky; Katherine Haffenreffer; Lyndsay A Avalos; Susan E Andrade
Journal:  Arch Womens Ment Health       Date:  2013-02-07       Impact factor: 3.633

Review 7.  Neuroimaging biomarkers for early drug development in schizophrenia.

Authors:  Jason R Tregellas
Journal:  Biol Psychiatry       Date:  2013-10-04       Impact factor: 13.382

8.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Authors:  Taishiro Kishimoto; Alfred Robenzadeh; Claudia Leucht; Stefan Leucht; Koichiro Watanabe; Masaru Mimura; Michael Borenstein; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2012-12-17       Impact factor: 9.306

9.  The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

Authors:  Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

Review 10.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.